Melane Sampson, Author at BioTuesdays

Executive Moves

Dr. Thomas J. Errico elected electroCore’s chairman of the board; Peter Cuneo retires

electroCore (NASDAQ: ECOR) has announced the election of Thomas J. Errico, MD, as chairman of the board and the departure of Peter Cuneo from its board of directors (BOD). According to electroCore, Mr. Cuneo will...

September 5, 2025

Developments

Vyome announces positive interim data on VT-1953 in MFW

Vyome Holdings (NASDAQ: HIND) has announced the interim results from its investigator –initiated Phase 2 Proof of Concept study of VT-1953 topical gel in patients with malignant fungating wounds (MFW). According to...

September 4, 2025

Developments

Lyell initiates Phase 3 CAR T-cell therapy trial in R/R LBCL; forms expert steering committee

Lyell Immunopharma (NASDAQ: LYEL) has announced the initiation of PiNNACLE—H2H, a Phase 3 head-to-head CAR T-cell therapy randomized controlled trial evaluating rondecabtagene autoleucel (ronde-cel, also known as...

September 3, 2025

Executive Moves

Adagene appoints Dr. Axel Hoos as executive advisor

Adagene (NASDAQ: ADAG) has announced the appointment of immuno-oncology pioneer, Axel Hoos, MD, PhD, as executive advisor. Most recently, Dr. Hoos served as CEO of Scorpion Therapeutics, which was acquired by Eli Lilly...

September 3, 2025

Executive Moves

Dr. Barbara Krebs-Pohl joins CASI’s BOD

CASI Pharmaceuticals (NASDAQ: CASI) has announced the appointment of Barbara Krebs-Pohl, PhD, as an independent director to its board of directors (BOD). Dr. Krebs-Pohl brings more than 27 years of leadership experience...

September 2, 2025

Developments

Oncolytics reveals updated safety data for pelareorep in GI tumors

Oncolytics Biotech (NASDAQ: ONCY) has announced that data continues to demonstrate a favorable safety profile for intravenously administered pelareorep across multiple gastrointestinal (GI) tumors, and in combination...

September 2, 2025

Feature

Likarda seeks acquisition partner to accelerate cell therapy delivery breakthrough

Closely held Likarda is advancing a novel modality for delivering cellular therapies—a proprietary, customizable hydrogel delivery system engineered for controlled release, immune protection, and high cell viability.

September 2, 2025

Developments

Providence Saint Joseph Medical Center acquires Perimeter’s OCT imaging technology

Providence Saint Joseph Medical Center—a nationally recognized, 383-bed, not-for-profit hospital in Burbank, California— has announced that it has adopted Perimeter Medical Imaging AI’s (TSXV: PINK; OTCQX: PYNKF)...

August 29, 2025

Executive Moves

Renowned surgical oncologist, Dr. Ted James, joins Perimeter as CMO

Perimeter Medical Imaging AI (TSX-V: PINK; OTCQX: PYNKF) has announced the appointment of Ted James, MD, MHCM, FACS, to the newly created position of chief medical officer (CMO). In this fractional role, Dr...

August 28, 2025

Developments

Firefly deploys NVIDIA L40S GPU acceleration to power next-gen CLEAR Platform

Firefly Neuroscience (NASDAQ: AIFF) has announced the unveiling of its new ‘CLEAR’ (CLeaning EEG ARtifacts) Platform, a proprietary next-generation preprocessing technology designed to deliver unrivalled...

August 26, 2025

Author - Melane Sampson

Dr. Thomas J. Errico elected electroCore’s chairman of the board; Peter Cuneo retires

Vyome announces positive interim data on VT-1953 in MFW

Lyell initiates Phase 3 CAR T-cell therapy trial in R/R LBCL; forms expert steering committee

Adagene appoints Dr. Axel Hoos as executive advisor

Dr. Barbara Krebs-Pohl joins CASI’s BOD

Oncolytics reveals updated safety data for pelareorep in GI tumors

Likarda seeks acquisition partner to accelerate cell therapy delivery breakthrough

Providence Saint Joseph Medical Center acquires Perimeter’s OCT imaging technology

Renowned surgical oncologist, Dr. Ted James, joins Perimeter as CMO

Firefly deploys NVIDIA L40S GPU acceleration to power next-gen CLEAR Platform

Subscribe